JLL vs MYGN · P/E 23, rev $13.31B vs rev $837.6M
Jones Lang LaSalle Incorporated (JLL) versus Myriad Genetics Inc (MYGN) — a side-by-side from cached financials, not a winner call.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
Latest reported JLL revenue for 2026-06-30 was $13.31B. Net income was $373.7M. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Latest reported MYGN revenue for 2024-12-31 was $837.6M. Net income was -$127.3M. Revenue was up 11.2% from 2023-12-31 to 2024-12-31. MYGN currently screens at market cap $413.7M.
JLL currently screens at market cap $12.12B and trailing P/E 23.0. MYGN currently screens at market cap $413.7M.
Not investment advice. Open the JLL and MYGN stock pages for the full models.
Not investment advice.